HAP Trading’s Astria Therapeutics ATXS Stock Holding History

HAP Trading’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-306,700	Closed	-$315K	–	676
2024 Q1	$315K	Buy	+306,700	New	+$3.82M	0.04%	231

Other funds holding ATXS

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

HAP Trading's ATXS Position: Q2 2024 in Review

HAP Trading sold out of Astria Therapeutics (ATXS) in Q2 2024, closing a stake of 19,096 shares — an estimated $269K sold.

HAP Trading first reported a position in ATXS in Q1 2024 and held it in 1 quarter. The position peaked at $269K in Q1 2024. 100 funds tracked by Wall St. Rank hold ATXS as of Q2 2024.

HAP Trading reported no remaining Astria Therapeutics position as of Q2 2024 after selling out during the quarter.
HAP Trading sold 19,096 Astria Therapeutics shares in Q2 2024, an estimated $269K.
HAP Trading first reported a position in Astria Therapeutics in Q1 2024 and held it in 1 quarter.
HAP Trading's Astria Therapeutics position peaked at $269K in Q1 2024.
100 funds tracked by Wall St. Rank held Astria Therapeutics as of Q2 2024.

Based on HAP Trading's 13F filing for Q2 2024, filed 14 Aug 2024.